A Phase 3 interventional study of APF530 and dexamethasone in Nausea and Vomiting and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Heron Therapeutics. Completed at 52 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Heron Therapeutics · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 290 studies in Nausea with a site in United States — 29 open to participants now, 32 under way, 8 of them phase 3. Nausea · United States.
Among the 290 studies in Nausea with a site in United States, this one is the 6th largest by enrollment of the 260 interventional ones that give a count, is one of 18 that started in 2006, is one of 40 in phase 3, and was the 33rd registered.
644 studies on the registry are indexed under Nausea; 85 are open to participants now.
Browse Nausea studies →29 of the 290 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Nausea studies recruiting now, 22 (42%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
290 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 62 · Phase 3 49 · Phase 4 38
First in 1999; this study’s year is marked. 18 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,428 is above the median of 96 across 544 interventional studies indexed under Nausea.
Median enrollment 86 across the 260 interventional studies, 106 across the 25 observational. Of the 227 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 290 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
Heron Therapeutics has 1 study filed under Nausea — fewer than ten, so there is no comparison to draw.
14 of the studies in Nausea with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT06588413Phase 3Augusta UniversityOlanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan | 2027-10 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 290 studies in Nausea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, placebo-controlled, double-blind, parallel-group, multicenter study. Patients are stratified according to emetogenicity of scheduled chemotherapy (moderate-risk [level 3 or 4] vs high-risk [level 5]). Patients are randomized to 1 of 3 treatment arms (I, II, and III). Patients who are randomized to receive palonosetron hydrochloride during chemotherapy course 1 (arm I) are then re-randomized to 1 of 2 treatment arms (II and III) after chemotherapy course 1 to receive treatment during chemotherapy courses 2-4.
Patients receive palonosetron hydrochloride or APF530 and/or placebo 30-60 minutes before the start of chemotherapy. Patients receive dexamethasone 30-90 minutes before the start of chemotherapy.
A subset of patients undergo blood collection periodically during study for analysis of plasma APF530 concentration.
Quality of life is assessed on day 5 after completion of chemotherapy course 1.
After completion of study treatment, patients are followed at approximately 30 days.
DISEASE CHARACTERISTICS:
or cytologically confirmed malignant disease
Scheduled to receive a single day of moderately or highly emetogenic chemotherapy regimen (for ≤ 4 courses)
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
Drug: dexamethasone · Drug: Palonosetron Hydrochloride · Other: placebo
Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
Drug: APF530 · Drug: dexamethasone · Other: placebo
Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
Drug: APF530 · Drug: dexamethasone · Other: placebo
Given subcutanously
Given IV and orally
Given IV
Given subcutanously or IV
Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1
Complete Response is defined as no emetic episodes and no use of rescue medications
Time frame: 0-24 Hours
Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1
Complete Response is defined as no emetic episodes and no use of rescue medications
Time frame: 24-120 Hours
Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1
Complete control is defined as complete response with no more than mild nausea.
Time frame: 0-120 Hours
Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1
TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1. TR during delayed-onset phase is defined as Complete Response with no nausea during \>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.
Time frame: 0-120 Hours
Number of Emetic Episodes
Number of Emetic Episodes - days 1-5
Time frame: Days 1-5
Time to First Treatment Failure
Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration
Time frame: 0-120 Hours
First and Overall Use of Rescue Medication
Time frame: 0-120 Hours
Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)
Maximum severity of nausea, days 1-5
Time frame: 0-120 Hours
Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses
Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles Complete Response is defined as no emetic episodes and no use of rescue medications
Time frame: 0-120 Hours
Quality of Life and the Impact of Nausea and Vomiting on Day 5
Functional Living Index
Time frame: 5 days
Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1
Subject who were very satisfied on Day 1
Time frame: 0- 24 Hours
| Milestone | APF530 5 mg | APF530 10 mg | Aloxi 0.25 mg |
|---|---|---|---|
| Started | 475 | 481 | 472 |
| Completed | 453 | 459 | 454 |
| Not completed | 22 | 22 | 18 |
| Milestone | APF530 5 mg | APF530 10 mg | Aloxi 0.25 mg |
|---|---|---|---|
| Started | 584 | 565 | 0 |
| Completed | 528 | 515 | 0 |
| Not completed | 56 | 50 | 0 |
Complete Response is defined as no emetic episodes and no use of rescue medications
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly |
|---|---|---|---|---|---|---|
| Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1 | 160 | 163 | 156 | 178 | 195 | 192 |
Complete Response is defined as no emetic episodes and no use of rescue medications
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly |
|---|---|---|---|---|---|---|
| Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1 | 110 | 125 | 120 | 148 | 164 | 158 |
Complete control is defined as complete response with no more than mild nausea.
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly |
|---|---|---|---|---|---|---|
| CC during acute Phase | 154 | 152 | 147 | 170 | 183 | 184 |
| CC during the delayed-onset phase | 100 | 115 | 107 | 138 | 150 | 147 |
| CC during the overall risk period | 93 | 107 | 99 | 127 | 138 | 136 |
TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1. TR during delayed-onset phase is defined as Complete Response with no nausea during \>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly |
|---|---|---|---|---|---|---|
| TR during acute phase | 135 | 121 | 113 | 141 | 146 | 158 |
| TR during the delayed-onset phase | 76 | 89 | 73 | 115 | 113 | 122 |
| TR during the overall risk period | 68 | 79 | 65 | 103 | 101 | 117 |
Number of Emetic Episodes - days 1-5
| Number of Emetic Episodes | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly |
|---|---|---|---|---|---|---|
| Number of Emetic Episodes | 3.4 ± 8.03 | 3.1 ± 9.35 | 2.1 ± 5.12 | 2.3 ± 6.69 | 2.4 ± 7.87 | 2.5 ± 7.15 |
Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration
| Proportion of subjects event free | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 - Highly |
|---|---|---|---|---|---|---|
| 24 Hours | 0.738 | 0.763 | 0.755 | 0.781 | 0.811 | 0.803 |
| 48 Hours | 0.636 | 0.659 | 0.635 | 0.706 | 0.723 | 0.714 |
| 72 Hours | 0.533 | 0.564 | 0.567 | 0.649 | 0.685 | 0.672 |
| 96 Hours | 0.485 | 0.550 | 0.534 | 0.618 | 0.668 | 0.634 |
| 120 Hours | 0.485 | 0.540 | 0.529 | 0.600 | 0.647 | 0.620 |
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 - Highly |
|---|---|---|---|---|---|---|
| Used Rescue Medication, 0-24 hours | 42 | 37 | 41 | 35 | 23 | 25 |
| Used Rescue Medication, 24-120 hours | 83 | 69 | 63 | 60 | 42 | 42 |
| Used Rescue Medication, 0-120 hours | 89 | 76 | 72 | 71 | 45 | 49 |
Maximum severity of nausea, days 1-5
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 - Highly |
|---|---|---|---|---|---|---|
| None | 78 | 85 | 66 | 105 | 102 | 121 |
| Mild | 45 | 53 | 68 | 53 | 68 | 53 |
| Moderate | 59 | 40 | 46 | 48 | 37 | 39 |
| Severe | 30 | 32 | 24 | 13 | 28 | 19 |
Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles Complete Response is defined as no emetic episodes and no use of rescue medications
| participants with overall CR | Cycles 1, 2, 3 and 4 - Moderately | Cycles 1, 2, 3, and 4 - Moderately | Cycles 1, 2, 3 and 4 - Highly | Cycles 1, 2, 3, and 4 - Highly |
|---|---|---|---|---|
| Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses | 34 | 35 | 56 | 52 |
Functional Living Index
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 - Highly |
|---|---|---|---|---|---|---|
| No nausea impact on daily life | 112 | 127 | 120 | 142 | 142 | 159 |
| No vomiting impact on daily life | 157 | 162 | 160 | 173 | 182 | 191 |
Subject who were very satisfied on Day 1
| participants | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 - Highly |
|---|---|---|---|---|---|---|
| Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1 | 101 | 113 | 98 | 128 | 128 | 135 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cycle 1 APF530 5 mg | — | 42/464 (9.1%) | 335/464 (72.2%) |
| Cycle 1 APF530 10 mg | — | 36/468 (7.7%) | 349/468 (74.6%) |
| Cycle 1 Aloxi 0.25 mg | — | 27/472 (5.7%) | 313/472 (66.3%) |
| Cycles 2-4 APF530 5 mg | — | 61/528 (11.6%) | 422/528 (79.9%) |
| Cycle 2-4 APF530 10 mg | — | 73/515 (14.2%) | 413/515 (80.2%) |
| Event | Cycle 1 APF530 5 mg | Cycle 1 APF530 10 mg | Cycle 1 Aloxi 0.25 mg | Cycles 2-4 APF530 5 mg | Cycle 2-4 APF530 10 mg |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/464 | 7/468 | 3/472 | 5/528 | 8/515 |
| PneumoniaInfections and infestations | 0/464 | 1/468 | 0/472 | 7/528 | 4/515 |
| NeutropeniaBlood and lymphatic system disorders | 2/464 | 1/468 | 2/472 | 2/528 | 6/515 |
| DehydrationMetabolism and nutrition disorders | 1/464 | 2/468 | 2/472 | 4/528 | 6/515 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/464 | 1/468 | 0/472 | 0/528 | 6/515 |
| AnaemiaBlood and lymphatic system disorders | 2/464 | 0/468 | 2/472 | 6/528 | 2/515 |
| VomitingGastrointestinal disorders | 1/464 | 4/468 | 1/472 | 1/528 | 3/515 |
| SepsisInfections and infestations | 1/464 | 1/468 | 2/472 | 4/528 | 1/515 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/464 | 0/468 | 0/472 | 4/528 | 0/515 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/464 | 3/468 | 1/472 | 4/528 | 1/515 |
| Event | Cycle 1 APF530 5 mg | Cycle 1 APF530 10 mg | Cycle 1 Aloxi 0.25 mg | Cycles 2-4 APF530 5 mg | Cycle 2-4 APF530 10 mg |
|---|---|---|---|---|---|
| Injection site bruisingGeneral disorders | 78/464 | 93/468 | 41/472 | 124/528 | 153/515 |
| FatigueGeneral disorders | 62/464 | 62/468 | 52/472 | 80/528 | 94/515 |
| Injection site noduleGeneral disorders | 22/464 | 50/468 | 3/472 | 57/528 | 90/515 |
| AnaemiaBlood and lymphatic system disorders | 46/464 | 42/468 | 34/472 | 86/528 | 87/515 |
| AlopeciaSkin and subcutaneous tissue disorders | 19/464 | 31/468 | 25/472 | 82/528 | 69/515 |
| ConstipationGastrointestinal disorders | 61/464 | 72/468 | 62/472 | 78/528 | 79/515 |
| NauseaGastrointestinal disorders | 55/464 | 58/468 | 41/472 | 66/528 | 73/515 |
| DiarrhoeaGastrointestinal disorders | 47/464 | 44/468 | 39/472 | 51/528 | 69/515 |
| Injection site erythemaGeneral disorders | 33/464 | 51/468 | 14/472 | 58/528 | 61/515 |
| AstheniaGeneral disorders | 23/464 | 21/468 | 30/472 | 60/528 | 39/515 |
Modified Intent-to-Treat Population
| Age, Continuous(years) | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.8 ± 12.80 | 55.1 ± 12.79 | 57.3 ± 12.36 | 57.6 ± 13.35 | 56.8 ± 13.20 | 58.1 ± 13.74 | 56.62 ± 13.04 |
| Sex: Female, Male(Participants) | Cycle 1 APF530 5 mg - Moderately | Cycle 1 APF530 10 mg - Moderately | Cycle 1 Aloxi 0.25 mg - Moderately | Cycle 1 APF530 5 mg - Highly | Cycle 1 APF530 10 mg - Highly | Cycle 1 Aloxi 0.25 Highly | Total |
|---|---|---|---|---|---|---|---|
| Female | 189 | 177 | 177 | 153 | 152 | 158 | 1006 |
| Male | 25 | 35 | 31 | 76 | 88 | 80 | 335 |
Plan to share: No
The record gives a start of Jun 2006, a primary completion of Sep 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 8 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.